AstraZeneca, Sputnik V ''mix & match'' trials show no serious adverse events

6 122
Representational Image

DTMT Network

The Russian Direct Investment Fund (RDIF) on July 30, 2021 said that interim analysis of the data demonstrates a high safety profile for the combined use of the AstraZeneca and Sputnik V COVID-19 vaccines with no serious adverse events or cases of coronavirus after vaccination

.

Russia's sovereign wealth fund announced initial safety results of the world's first study of a combination between the COVID-19 vaccine developed jointly with the University of Oxford and the first component of the Russian COVID-19 vaccine (Sputnik Light vaccine based on human adenovirus serotype 26) in the Republic of Azerbaijan.

“The heterogeneous boosting approach (“vaccine cocktail”) using human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component was at the core of Sputnik V, the world’s first registered vaccine against coronavirus,” RDIF said in a statement.

The RDIF initiated the study in December 2020. The first partnership of this kind was concluded in December 2020 in the presence of Russian President Vladimir Putin.
RDIF, The Gamaleya Center, AstraZeneca and R-Pharm signed a Memorandum of Intent aimed at cooperation in vaccine development.

The RDIF was the first in the World to initiate such a study in December 2020.

“The first partnership of this kind was concluded in December 2020 in the presence of the President of Russia Vladimir Putin. RDIF, The Gamaleya Center, AstraZeneca and R-Pharm signed a Memorandum of Intent aimed at cooperation in vaccine development,” said RDIF's statement.

Studies on the safety and immunogenicity of the combination of the AstraZeneca vaccine and the first component of the Sputnik V vaccine in Azerbaijan began in February 2021.
“To date, 50 volunteers have been vaccinated and new participants are invited to join the trial. Interim analysis of the data demonstrates a high safety profile for the combined use of the vaccines with no serious adverse events or cases of coronavirus after vaccination.”


0 Comments

  1. Be first to post your comments

Your Comment

Your email address will not be published. Required fields are marked *

7+8

higlobin

Back to Top